Imperial College London
Alternate

ProfessorMartinCowie

Faculty of Medicine, National Heart & Lung Institute

Visiting Professor
 
 
 
//

Contact

 

+44 (0)20 7351 8856m.cowie

 
 
//

Assistant

 

Mr Jacob Chapman +44 (0)20 7351 8856

 
//

Location

 

Chelsea WingRoyal Brompton Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Cowie:2022:10.1002/ehf2.13748,
author = {Cowie, MR and Flett, A and Cowburn, P and Foley, P and Chandrasekaran, B and Loke, I and Critoph, C and Gardner, RS and Guha, K and Betts, TR and Carr-White, G and Zaidi, A and Lim, HS and Hayward, C and Patwala, A and Rogers, D and Pettit, S and Gazzola, C and Henderson, J and Adamson, PB},
doi = {10.1002/ehf2.13748},
journal = {ESC Heart Failure},
pages = {48--56},
title = {Real-world evidence in a national health service: results of the UK CardioMEMS HF System Post-Market Study},
url = {http://dx.doi.org/10.1002/ehf2.13748},
volume = {9},
year = {2022}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - AimsThe CardioMEMS HF System Post-Market Study (COAST) was designed to evaluate the safety, effectiveness, and feasibility of haemodynamic-guided heart failure (HF) management using a small sensor implanted in the pulmonary artery of New York Heart Association (NYHA) Class III HF patients in the UK, Europe, and Australia.Methods and resultsCOAST is a prospective, international, multicentre, open-label clinical study (NCT02954341). The primary clinical endpoint compares annualized HF hospitalization rates after 1 year of haemodynamic-guided management vs. the year prior to sensor implantation in patients with NYHA Class III symptoms and a previous HF hospitalization. The primary safety endpoints assess freedom from device/system-related complications and pressure sensor failure after 2 years. Results from the first 100 patients implanted at 14 out of the 15 participating centres in the UK are reported here. At baseline, all patients were in NYHA Class III, 70% were male, mean age was 69 ± 12 years, and 39% had an aetiology of ischaemic cardiomyopathy. The annualized HF hospitalization rate after 12 months was 82% lower [95% confidence interval 72–88%] than the previous 12 months (0.27 vs. 1.52 events/patient-year, respectively, P < 0.0001). Freedom from device/system-related complications and pressure sensor failure at 2 years was 100% and 99%, respectively.ConclusionsRemote haemodynamic-guided HF management, using frequent assessment of pulmonary artery pressures, was successfully implemented at 14 specialist centres in the UK. Haemodynamic-guided HF management was safe and significantly reduced hospitalization in a group of high-risk patients. These results support implementation of this innovative remote management strategy to improve outcome for patients with symptomatic HF.Clinical registration number: ClinicalTrials.gov identifier: NCT02954341.
AU  - Cowie,MR
AU  - Flett,A
AU  - Cowburn,P
AU  - Foley,P
AU  - Chandrasekaran,B
AU  - Loke,I
AU  - Critoph,C
AU  - Gardner,RS
AU  - Guha,K
AU  - Betts,TR
AU  - Carr-White,G
AU  - Zaidi,A
AU  - Lim,HS
AU  - Hayward,C
AU  - Patwala,A
AU  - Rogers,D
AU  - Pettit,S
AU  - Gazzola,C
AU  - Henderson,J
AU  - Adamson,PB
DO  - 10.1002/ehf2.13748
EP  - 56
PY  - 2022///
SN  - 2055-5822
SP  - 48
TI  - Real-world evidence in a national health service: results of the UK CardioMEMS HF System Post-Market Study
T2  - ESC Heart Failure
UR  - http://dx.doi.org/10.1002/ehf2.13748
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000728211500001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - https://onlinelibrary.wiley.com/doi/10.1002/ehf2.13748
UR  - http://hdl.handle.net/10044/1/95297
VL  - 9
ER  -
Download